Northvale, NJ – According to filings with the U.S. Securities and Exchange Commission, Elite Pharmaceuticals is raising $26,000,000.00 in new funding. Sources indicate as part of senior management Chief Financial Officer, Carter Ward played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Elite Pharmaceuticals

Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company developing a pipeline of proprietary pharmacological abuse-deterrent opioid products and niche generic products. Elite specializes in oral sustained and controlled release drug products with high barriers to entry. Elite owns generic which have been licensed to TAGI Pharma and Glenmark Pharmaceuticals Inc., USA., and Lannett Company, Inc.

To learn more about Elite Pharmaceuticals, visit http://www.elitepharma.com/

Contact:
Carter Ward, Chief Financial Officer
201-750-2646
cward@elitepharma.com
https://www.linkedin.com/in/carterjward/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved